Ivabradina Eg

Ivabradine, the active ingredient in Ivabradina Eg, is an If (funny) channel inhibitor presented as an oral tablet for oral use. It selectively inhibits the cardiac pacemaker If current in the sino‑atrial node, leading to heart‑rate reduction without affecting myocardial contractility. It is employed in the management of chronic stable angina pectoris and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradina Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for cardiovascular therapeutics across multiple continents.

Ivabradine is used to manage cardiovascular conditions where heart‑rate reduction improves outcomes. - Chronic stable angina pectoris: reduces frequency of angina attacks and improves exercise tolerance. - Heart failure with reduced ejection fraction: lowers heart rate, alleviating symptoms and supporting cardiac function.

Ivabradine may be associated with several adverse reactions, ranging from frequent, mild events to rare, serious conditions.

Common Side Effects: - Bradycardia: slower than intended heart rate. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Symptomatic bradycardia: may cause syncope or hypotension. - Atrial fibrillation: irregular heart rhythm. - Allergic reactions: rash, pruritus, or anaphylaxis.

When prescribing ivabradine, clinicians should consider several precautionary measures to ensure patient safety. - Cardiac monitoring: assess resting heart rate before initiation and periodically during therapy. - Concomitant beta‑blockers: avoid excessive heart‑rate lowering by adjusting doses. - Severe hepatic impairment: use with caution as metabolism may be reduced. - Pregnancy and lactation: contraindicated unless benefits outweigh potential risks. - Drug interactions: review concomitant medications that affect CYP3A4 metabolism. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Ivabradine can interact with other medicines, influencing its plasma concentration or combined physiological effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ivabradine levels. - Concomitant diltiazem or verapamil: can cause pronounced bradycardia. - Other heart‑rate lowering agents (beta‑blockers, digoxin): risk of excessive bradycardia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may require dose adjustment. - QT‑prolonging drugs: monitor ECG for interval changes. - Hypotensive agents: observe for additive blood pressure reduction.